Demyelinating Autoimmune Diseases, CNS D020278

Related MeSH Hierarchy (4)

Diseases [C] » Nervous System Diseases [C10] » Autoimmune Diseases of the Nervous System » Demyelinating Autoimmune Diseases, CNS

Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Brain Diseases » Leukoencephalopathies » Demyelinating Autoimmune Diseases, CNS

Diseases [C] » Nervous System Diseases [C10] » Demyelinating Diseases » Demyelinating Autoimmune Diseases, CNS

Diseases [C] » Immune System Diseases [C20] » Autoimmune Diseases » Autoimmune Diseases of the Nervous System » Demyelinating Autoimmune Diseases, CNS

Description

Conditions characterized by loss or dysfunction of myelin (see MYELIN SHEATH) in the brain, spinal cord, or optic nerves secondary to autoimmune mediated processes. This may take the form of a humoral or cellular immune response directed toward myelin or OLIGODENDROGLIA associated autoantigens.   MeSH

Hierarchy View

Subtype Terms (7)

Leukoencephalitis, Acute Hemorrhagic
 

Multiple Sclerosis
332 drugs (172 approved, 160 experimental)

Myelitis, Transverse
7 drugs (5 approved, 2 experimental)

Neuromyelitis Optica
43 drugs (28 approved, 15 experimental)


Phase 4 Indicated Drugs (1)


Organization Involved with Phase 4 Indications (3)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.